TDP-43: a novel neurodegenerative proteinopathy

被引:99
|
作者
Forman, Mark S. [1 ,2 ]
Trojanowski, John Q. [1 ,2 ]
Lee, Virginia M-Y [1 ,2 ]
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.conb.2007.08.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Over the past decade, it has become clear that there is a significant overlap in the clinical spectrum of frontotemporal lobar degeneration and amyotrophic lateral sclerosis (ALS). The identification of TDP-43 as the major disease protein in the pathology of both frontotemporal lobar degeneration with ubiquitin inclusions and ALS provides the first molecular link for these diseases. Pathological TDP-43 is abnormally phosphorylated, ubiquitinated, and cleaved to generate carboxy-terminal fragments in affected brain regions. The normal nuclear expression of TDP-43 is also reduced leading to the hypothesis that sequestration of TDP-43 in pathological inclusions contributes to disease pathogenesis. Thus, TDP-43 is the newest member of the growing list of neurodegenerative proteinopathies, but unique in that it lacks features of brain amyloidosis.
引用
收藏
页码:548 / 555
页数:8
相关论文
共 50 条
  • [21] Optogenetic Induction of TDP-43 Proteinopathy In Vivo
    Otte, Charlton
    Mann, Jacob
    Pandey, Udai
    Donnelly, Christopher
    NEUROLOGY, 2019, 92 (15)
  • [22] Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
    Hayes, Lindsey R.
    Kalab, Petr
    NEUROTHERAPEUTICS, 2022, 19 (04) : 1061 - 1084
  • [23] TDP-43 Proteinopathy Specific Biomarker Development
    Cordts, Isabell
    Wachinger, Annika
    Scialo, Carlo
    Lingor, Paul
    Polymenidou, Magdalini
    Buratti, Emanuele
    Feneberg, Emily
    CELLS, 2023, 12 (04)
  • [24] The basis of clinicopathological heterogeneity in TDP-43 proteinopathy
    Kawakami, Ito
    Arai, Tetsuaki
    Hasegawa, Masato
    ACTA NEUROPATHOLOGICA, 2019, 138 (05) : 751 - 770
  • [25] TDP-43 derived α-helical peptides: A novel strategy to prevent TDP-43 aggregation in neurodegenerative disorders
    Salaikumaran, Muthu Raj
    Gopal, Pallavi P.
    BIOPHYSICAL JOURNAL, 2024, 123 (03) : 169A - 169A
  • [26] Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
    Lindsey R. Hayes
    Petr Kalab
    Neurotherapeutics, 2022, 19 : 1061 - 1084
  • [27] NOVEL IN VITRO AND IN VIVO MODELS OF ALS ASSOCIATED WITH TDP-43 PROTEINOPATHY
    Hewamadduma, C.
    Higgenbottom, C. A. A.
    Moens, C.
    Helde, K.
    Raman, R.
    Tennore, R.
    Grierson, A.
    Shaw, P. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (03):
  • [28] Identification of TDP-43 modifying kinases in a C. elegans model of TDP-43 proteinopathy.
    Liachko, Nicole F.
    Guthrie, Chris R.
    Kraemer, Brian C.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2012, 33 : 31 - 32
  • [29] Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy
    Katsumata, Yuriko
    Abner, Erin L.
    Karanth, Shama
    Teylan, Merilee A.
    Mock, Charles N.
    Cykowski, Matthew D.
    Lee, Edward B.
    Boehme, Kevin L.
    Mukherjee, Shubhabrata
    Kauwe, John S. K.
    Kryscio, Richard J.
    Schmitt, Frederick A.
    Fardo, David W.
    Nelson, Peter T.
    ACTA NEUROPATHOLOGICA, 2020, 140 (05) : 659 - 674
  • [30] Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy
    Yuriko Katsumata
    Erin L. Abner
    Shama Karanth
    Merilee A. Teylan
    Charles N. Mock
    Matthew D. Cykowski
    Edward B. Lee
    Kevin L. Boehme
    Shubhabrata Mukherjee
    John S. K. Kauwe
    Richard J. Kryscio
    Frederick A. Schmitt
    David W. Fardo
    Peter T. Nelson
    Acta Neuropathologica, 2020, 140 : 659 - 674